Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial.

Abstract

OBJECTIVE:

To study the long-term effect of 16 weeks of etanercept treatment on disease activity and radiographic changes in patients with suspected non-radiographic axial spondyloarthritis (nr-axSpA).

METHOD:

Eighty patients with inflammatory back pain and suspected nr-axSpA, with a Bath Ankylosing Disease Activity Index (BASDAI) ≥ 4, received etanercept (n = 40) 25 mg twice weekly or placebo (n = 40) for 16 weeks. They were followed without treatment restrictions after 24 weeks, for up to 3 years. Comparisons were made between patients who received etanercept or placebo in the first period, and changes in BASDAI, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Metrology Index (BASMI), function, and radiographic changes in the spine [according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)] and sacroiliac joints (Bath Ankylosing Spondylitis Radiology Index (BASRI).

RESULTS:

After 3 years of follow-up, 84% of the patients were diagnosed with SpA, predominantly axSpA. Biological treatment was started after 24 weeks in 30% of patients. Disease activity scores after 3 years did not reveal significant differences between the initial randomization groups in mean BASDAI scores (mean difference 0.9, 95% CI -1.1;0.7, p = 0.6) and ASDAS (mean ASDAS 0.3, 95% CI 0.6;3.1, p = 0.5). BASMI and function scores remained stable over 3 years. No differences in radiographic changes of the sacroiliac joints or spine were observed over 3 years between the two groups.

CONCLUSION:

A short course of etanercept in patients with suspected nr-axSpA did not affect disease activity, the chance of biological treatment, or radiographic progression after 3 years of follow-up.

• Authors: T Rusman, Mac van der Weijden, M T Nurmohamed, C J van Denderen, Rbm Landewé, P M Bet, Cma van der Bijl, C J van der Laken, I E van der Horst-Bruinsma
• Journal: Scandinavian journal of rheumatology (Scand J Rheumatol) Vol. 52 Issue 2 Pg. 137-141 (03 2023) ISSN: 1502-7732 [Electronic] England
• PMID: 35543102 (Publication Type: Randomized Controlled Trial, Journal Article)

Chemical References

• Etanercept

Topics

• Humans
• Spondylitis, Ankylosing (diagnostic imaging, drug therapy)
• Etanercept (therapeutic use)
• Spondylarthritis (diagnostic imaging, drug therapy)
• Non-Radiographic Axial Spondyloarthritis
• Pain
• Disease Progression
• Severity of Illness Index